Bisphosphonates show up on Step exams because they’re one of the cleanest examples of “mechanism → clinical use → adverse effects” medicine: they stick to bone, shut down osteoclasts, and then predictably cause issues in places where bone is actively remodeled (jaw) or where pills sit (esophagus). If you can connect the physiology of bone turnover to the pharmacology, these questions become freebies.
Big Picture: Bone Remodeling in One Minute (Why These Drugs Work)
Bone is constantly remodeled via the coupled actions of:
- Osteoclasts: resorb bone (break it down)
- Osteoblasts: build bone (lay down osteoid → mineralize)
Key endocrine regulation (high yield):
- PTH indirectly increases osteoclast activity by stimulating osteoblasts to express RANKL, which activates osteoclasts via RANK.
- Calcitonin decreases osteoclast activity (minor player clinically).
- Vitamin D increases intestinal absorption of Ca/PO₄ and supports mineralization; in high amounts can increase bone resorption.
Clinical anchor: Most “bone drugs” for osteoporosis work by decreasing osteoclast-mediated resorption or by increasing osteoblast activity.
Bisphosphonates: Definition + Mechanism (Step-Ready)
What are bisphosphonates?
Synthetic analogs of pyrophosphate that have a high affinity for hydroxyapatite in bone—especially at sites of active remodeling.
Core mechanism (the Step 1 version)
Bisphosphonates inhibit osteoclast-mediated bone resorption.
More detail (useful for tricky questions):
- They bind to bone mineral and are taken up by osteoclasts during resorption.
- Nitrogen-containing bisphosphonates (most common in the US) inhibit farnesyl pyrophosphate synthase in the mevalonate pathway → impaired prenylation → osteoclast dysfunction + apoptosis.
Examples (know at least 2–3):
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic acid
- (Older/non-nitrogen: Etidronate—less tested)
First Aid cross-reference: Endocrine → Pharmacology → Osteoporosis drugs (bisphosphonates, denosumab, teriparatide, etc.). (Edition/page numbers vary.)
Indications (When to Use Bisphosphonates)
1) Osteoporosis (most common)
Especially in:
- Postmenopausal osteoporosis
- Glucocorticoid-induced osteoporosis
- Older adults with fragility fractures or low T-score
Exam clue: Patient with low bone mineral density + vertebral compression fracture → bisphosphonate is a classic first-line.
2) Paget disease of bone
High bone turnover disorder → bone pain, deformity, elevated ALP.
3) Hypercalcemia of malignancy
Especially when due to osteolytic metastases (e.g., breast cancer, multiple myeloma).
- Bisphosphonates are slower than calcitonin but provide more sustained control.
4) Prevention of skeletal-related events
In cancers with bone metastases (reduce fractures, pain).
Clinical Presentation & Diagnosis Pearls (How It’s Tested)
Bisphosphonates aren’t “diagnosed,” but Step questions test:
- The disease (osteoporosis/Paget/hypercalcemia malignancy)
- The best treatment
- The adverse effects + counseling
Osteoporosis: classic presentation & diagnosis
- Often asymptomatic until fracture
- Fragility fractures: vertebral compression, hip, wrist
- Diagnosis by DEXA scan
- Osteoporosis: T-score ≤ −2.5
Paget disease: classic presentation & diagnosis
- Bone pain, enlarged skull (↑ hat size), hearing loss
- Elevated ALP with normal Ca/PO₄/PTH (often)
- X-ray: mixed lytic/sclerotic lesions; “mosaic” pattern on histology (buzzword)
Hypercalcemia of malignancy: clue set
- Confusion, constipation, stones, bone pain
- Labs: ↑ Ca, ↓ PTH (often), may have ↑ PTHrP depending on cancer type
- If due to bone resorption: treat with IV bisphosphonate (e.g., zoledronic acid)
Administration Rules (Frequently Tested Counseling)
Oral bisphosphonates (alendronate, risedronate, ibandronate):
- Take first thing in the morning with a full glass of water
- Stay upright for at least 30 minutes
- Avoid food, drink (besides water), and other meds for a period after dosing
Why?
- They can cause esophagitis and have poor oral bioavailability.
IV option:
- Zoledronic acid is IV and used commonly in malignancy-related bone disease and some osteoporosis regimens.
Adverse Effects: High-Yield Associations (Know These Cold)
1) Esophagitis / esophageal ulceration
Classic vignette: Patient started alendronate and now has chest pain/odynophagia—didn’t remain upright.
2) Osteonecrosis of the jaw (ONJ)
- More common with high-dose IV bisphosphonates (oncology dosing) but can occur with long-term therapy.
- Often triggered by dental procedures (extractions/implants).
Step counseling pearl: Dental evaluation and good oral hygiene; consider dental work prior to high-dose/long-term antiresorptives.
3) Atypical femoral fractures
- Long-term oversuppression of remodeling → microdamage accumulation.
- Presents as thigh/groin pain preceding a low-energy fracture.
4) Hypocalcemia (especially IV)
- Particularly in patients with vitamin D deficiency or other risk factors.
5) Acute-phase reaction (flu-like symptoms)
- More associated with IV bisphosphonates (e.g., zoledronic acid).
Quick table: Bisphosphonates HY summary
| Feature | High-yield points |
|---|---|
| Mechanism | Bind hydroxyapatite; inhibit osteoclasts (nitrogen agents inhibit farnesyl pyrophosphate synthase) |
| Uses | Osteoporosis, Paget disease, hypercalcemia of malignancy, bone mets |
| Key AEs | Esophagitis, ONJ, atypical femur fracture, hypocalcemia, flu-like symptoms (IV) |
| Counseling | Take with water, stay upright 30 min, avoid eating immediately after |
“Bone Drugs” Beyond Bisphosphonates (Common Step Comparators)
Bisphosphonates are tested alongside denosumab, teriparatide, raloxifene, and calcitonin. Here’s how to keep them straight.
Denosumab
- Mechanism: Monoclonal antibody against RANKL → prevents osteoclast activation.
- Uses: Osteoporosis; also used in cancer-related bone disease.
- Adverse effects (HY):
- Hypocalcemia
- Osteonecrosis of the jaw
- Increased risk of infections (less commonly emphasized)
Exam trick: If a patient has severe renal impairment, denosumab is sometimes favored clinically—but for Step, focus on RANKL inhibition + ONJ/hypocalcemia.
First Aid cross-reference: Endocrine pharm → osteoporosis drugs; immunology tie-in: monoclonal antibody blocking RANKL.
Teriparatide (PTH analog)
- Mechanism: Recombinant PTH (1-34). Intermittent dosing → stimulates osteoblasts more than osteoclasts → increases bone formation.
- Use: Severe osteoporosis (especially high fracture risk).
- Adverse effects (HY):
- Osteosarcoma risk (seen in rats; Step loves this association)
- Hypercalcemia (possible)
Key physiology pearl:
- Continuous PTH → bone resorption (via RANKL)
- Intermittent PTH → bone formation
First Aid cross-reference: Endocrine physiology (PTH) + pharm (teriparatide).
Raloxifene (SERM)
- Mechanism: Estrogen agonist in bone → decreases bone resorption.
- Uses: Osteoporosis prevention/treatment; decreases breast cancer risk (ER+).
- Adverse effects (HY):
- Hot flashes
- Increased risk of thromboembolism
- Does not stimulate endometrium (contrast with tamoxifen).
First Aid cross-reference: Repro pharm (SERMs) + endocrine bone metabolism.
Calcitonin
- Mechanism: Decreases osteoclast activity.
- Uses: Less potent; sometimes used for pain in acute vertebral fractures, and in hypercalcemia as a short-term measure.
- Adverse effects: Generally mild; can cause flushing, nausea.
Step reality: Calcitonin is conceptually important but less likely to be the “best long-term osteoporosis drug” compared with bisphosphonates/denosumab/teriparatide.
Putting It All Together: Rapid-Fire Step Patterns
Pattern 1: “Postmenopausal woman + vertebral compression fracture”
- Diagnosis: Osteoporosis (DEXA T-score ≤ −2.5)
- First-line: Bisphosphonate
- Counsel: upright after taking; water only
Pattern 2: “Cancer patient with bone pain + very high calcium”
- Acute management: IV fluids ± calcitonin for rapid effect
- Sustained control: IV bisphosphonate (e.g., zoledronic acid) or denosumab
- Watch for: hypocalcemia, ONJ
Pattern 3: “Jaw pain after dental extraction in patient on zoledronic acid”
- Think: Osteonecrosis of the jaw
- Association: bisphosphonates (also denosumab)
Pattern 4: “Severe osteoporosis + multiple fractures despite bisphosphonate”
- Consider: Teriparatide (builds bone)
- Red flag association: osteosarcoma
Mini Comparison Table (Common Exam Differentials)
| Drug | Primary target | Net effect | Signature adverse association |
|---|---|---|---|
| Bisphosphonates | Osteoclasts (via bone binding; FPPS inhibition) | ↓ Bone resorption | Esophagitis, ONJ, atypical femur fractures |
| Denosumab | RANKL | ↓ Osteoclast activation | Hypocalcemia, ONJ |
| Teriparatide | PTH receptor (intermittent) | ↑ Bone formation | Osteosarcoma (rats) |
| Raloxifene | Estrogen receptor (bone agonist) | ↓ Resorption | VTE, hot flashes |
| Calcitonin | Osteoclast inhibition | ↓ Resorption | Flushing, nausea (less tested) |
High-Yield Takeaways (Memorize These)
- Bisphosphonates bind hydroxyapatite and inhibit osteoclasts → treat osteoporosis, Paget, hypercalcemia of malignancy.
- Classic adverse effects: esophagitis, osteonecrosis of the jaw, atypical femur fractures, hypocalcemia.
- Denosumab blocks RANKL (same clinical lane as bisphosphonates; also ONJ/hypocalcemia).
- Teriparatide is intermittent PTH → builds bone; linked to osteosarcoma on exams.
- For oral bisphosphonates: water + upright 30 minutes is a testable patient-safety detail.